Skip to main content
Top
Published in: BMC Infectious Diseases 1/2020

Open Access 01-12-2020 | Human Immunodeficiency Virus | Research article

A packaged intervention to improve viral load monitoring within a deeply rural health district of South Africa

Authors: J. Brijkumar, B. A. Johnson, Y. Zhao, J. Edwards, P. Moodley, K. Pathan, S. Pillay, K. G. Castro, H. Sunpath, D. R. Kuritzkes, M. Y. S. Moosa, V. C. Marconi

Published in: BMC Infectious Diseases | Issue 1/2020

Login to get access

Abstract

Background

The KwaZulu-Natal (KZN) province of South Africa has the highest prevalence of HIV infection in the world. Viral load (VL) testing is a crucial tool for clinical and programmatic monitoring. Within uMkhanyakude district, VL suppression rates were 91% among patients with VL data; however, VL performance rates averaged only 38·7%. The objective of this study was to determine if enhanced clinic processes and community outreach could improve VL monitoring within this district.

Methods

A packaged intervention was implemented at three rural clinics in the setting of the KZN HIV AIDS Drug Resistance Surveillance Study. This included file hygiene, outreach, a VL register and documentation revisions. Chart audits were used to assess fidelity. Outcome measures included percentage VL performed and suppressed. Each rural clinic was matched with a peri-urban clinic for comparison before and after the start of each phase of the intervention. Monthly sample proportions were modelled using quasi-likelihood regression methods for over-dispersed binomial data.

Results

Mkuze and Jozini clinics increased VL performance overall from 33·9% and 35·3% to 75·8% and 72·4%, respectively which was significantly greater than the increases in the comparison clinics (RR 1·86 and 1·68, p < 0·01). VL suppression rates similarly increased overall by 39·3% and 36·2% (RR 1·84 and 1·70, p < 0·01). The Chart Intervention phase showed significant increases in fidelity 16 months after implementation.

Conclusions

The packaged intervention improved VL performance and suppression rates overall but was significant in Mkuze and Jozini. Larger sustained efforts will be needed to have a similar impact throughout the province.
Appendix
Available only for authorised users
Literature
1.
go back to reference UNAIDS Data 2017. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS);2017. UNAIDS Data 2017. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS);2017.
2.
go back to reference HIV/AIDS/STI Dashboard Indicators National Feedback Per Province: 2016/17 Financial year quarter 2. District Health Information System, Department of Health Republic of South Africa; December 1, 2016 2016. HIV/AIDS/STI Dashboard Indicators National Feedback Per Province: 2016/17 Financial year quarter 2. District Health Information System, Department of Health Republic of South Africa; December 1, 2016 2016.
3.
go back to reference Analysis of Big Data for Better Targeting of ART Adherence Strategies: Spatial Clustering Analysis of Viral Load Suppression by South African Province, District, Sub-District and Facility (April 2014–March 2015). Washington, DC: World Bank; 2015. Analysis of Big Data for Better Targeting of ART Adherence Strategies: Spatial Clustering Analysis of Viral Load Suppression by South African Province, District, Sub-District and Facility (April 2014–March 2015). Washington, DC: World Bank; 2015.
4.
go back to reference Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 study team. ACTG virology Committee resistance and HIV-1 RNA working groups. J Infect Dis. 1996;174(4):704–12.CrossRef Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 study team. ACTG virology Committee resistance and HIV-1 RNA working groups. J Infect Dis. 1996;174(4):704–12.CrossRef
5.
go back to reference Gazzard B, Committee BW. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med. 2005;6(Suppl 2):1–61.CrossRef Gazzard B, Committee BW. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med. 2005;6(Suppl 2):1–61.CrossRef
6.
go back to reference Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272(5265):1167–70.CrossRef Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272(5265):1167–70.CrossRef
7.
go back to reference O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA cooperative study group on AIDS. Ann Intern Med. 1997;126(12):939–45.CrossRef O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA cooperative study group on AIDS. Ann Intern Med. 1997;126(12):939–45.CrossRef
8.
go back to reference In: nd, ed. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva 2016. In: nd, ed. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva 2016.
9.
go back to reference Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J Acquir Immune Defic Syndr. 2006;41(5):632–41.CrossRef Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J Acquir Immune Defic Syndr. 2006;41(5):632–41.CrossRef
10.
go back to reference Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339(6122):966–71.CrossRef Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339(6122):966–71.CrossRef
11.
go back to reference South Africa Global AIDS Response Progress Report (GARPR) 2015. Pretoria, South Africa: South African National AIDS Council (SANAC); 2015. South Africa Global AIDS Response Progress Report (GARPR) 2015. Pretoria, South Africa: South African National AIDS Council (SANAC); 2015.
12.
go back to reference HIV/AIDS/STI Dashboard Indicators National Feedback Per Province: 2016/17 Financial year quarter 2. District Health Information System; 01 December 2016. HIV/AIDS/STI Dashboard Indicators National Feedback Per Province: 2016/17 Financial year quarter 2. District Health Information System; 01 December 2016.
13.
go back to reference McCullagh P, Nelder JA. Generalized linear models. London ; New York: Chapman and Hall; 1983. McCullagh P, Nelder JA. Generalized linear models. London ; New York: Chapman and Hall; 1983.
14.
go back to reference Chimukangara B, Kharsany ABM, Lessells RJ, et al. Moderate-to-high levels of pretreatment HIV drug resistance in KwaZulu-Natal Province, South Africa. AIDS Res Hum Retroviruses. 2019;35(2):129–38.CrossRef Chimukangara B, Kharsany ABM, Lessells RJ, et al. Moderate-to-high levels of pretreatment HIV drug resistance in KwaZulu-Natal Province, South Africa. AIDS Res Hum Retroviruses. 2019;35(2):129–38.CrossRef
15.
go back to reference District Health Plan 2015/2016: Umkhanyakude District, Kwazulu-Natal. 2015. District Health Plan 2015/2016: Umkhanyakude District, Kwazulu-Natal. 2015.
16.
go back to reference Mutenda N, Bukowski A, Nitschke AM, et al. Assessment of the World Health Organization's HIV drug resistance early warning indicators in Main and decentralized outreach antiretroviral therapy sites in Namibia. PLoS One. 2016;11(12):e0166649.CrossRef Mutenda N, Bukowski A, Nitschke AM, et al. Assessment of the World Health Organization's HIV drug resistance early warning indicators in Main and decentralized outreach antiretroviral therapy sites in Namibia. PLoS One. 2016;11(12):e0166649.CrossRef
17.
go back to reference Pham MD, Romero L, Parnell B, Anderson DA, Crowe SM, Luchters S. Feasibility of antiretroviral treatment monitoring in the era of decentralized HIV care: a systematic review. AIDS Res Ther. 2017;14(1):3.CrossRef Pham MD, Romero L, Parnell B, Anderson DA, Crowe SM, Luchters S. Feasibility of antiretroviral treatment monitoring in the era of decentralized HIV care: a systematic review. AIDS Res Ther. 2017;14(1):3.CrossRef
Metadata
Title
A packaged intervention to improve viral load monitoring within a deeply rural health district of South Africa
Authors
J. Brijkumar
B. A. Johnson
Y. Zhao
J. Edwards
P. Moodley
K. Pathan
S. Pillay
K. G. Castro
H. Sunpath
D. R. Kuritzkes
M. Y. S. Moosa
V. C. Marconi
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2020
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-05576-5

Other articles of this Issue 1/2020

BMC Infectious Diseases 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.